BioLineRx (BLRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.01, -1.95% vs the prior close of $2.05.
- Volume 12.58K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BLRX dips 2.0% to $2.01, a 52-week low, 5 down days in a row. Closed at $2.01, -1.95% vs the prior close of $2.05. Day range $1.99–$2.30, opened at $2.30.
BLRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BLRX dips 2.0% to $2.01, a 52-week low, 5 down days in a row
- Closed at $2.01, -1.95% vs the prior close of $2.05. Day range $1.99–$2.30, opened at $2.30.
- Volume was 12.58K shares, 0.6x its 50-day average of 19.61K.
- Price is -20.7% vs its 50-day average ($2.54) and -27.7% vs its 200-day average ($2.78).
- 52-week range $1.95–$4.07; today's close sits at 3% of that range, 50.6% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — BLRX dips 1.4% to $2.05, a 52-week low, 4 down days in a row
- Closed at $2.05, -1.44% vs the prior close of $2.08. Day range $1.95–$2.17, opened at $2.03.
- Volume was 28.80K shares, 1.5x its 50-day average of 19.13K.
- Price is -19.6% vs its 50-day average ($2.55) and -26.4% vs its 200-day average ($2.79).
- 52-week range $1.95–$4.09; today's close sits at 5% of that range, 49.9% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — BLRX slides 4.1% to $2.08, a 52-week low, 3 down days in a row
- Closed at $2.08, -4.15% vs the prior close of $2.17. Day range $2.01–$2.18, opened at $2.18.
- Volume was 23.50K shares, 1.3x its 50-day average of 18.74K.
- Price is -18.9% vs its 50-day average ($2.56) and -25.5% vs its 200-day average ($2.79).
- 52-week range $2.01–$4.09; today's close sits at 3% of that range, 49.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — BLRX ends flat (+0.0%) to $2.17
- Closed at $2.17, +0.00% vs the prior close of $2.17. Day range $2.11–$2.27, opened at $2.27.
- Volume was 11.70K shares, 0.6x its 50-day average of 18.61K.
- Price is -15.8% vs its 50-day average ($2.58) and -22.4% vs its 200-day average ($2.79).
- 52-week range $2.11–$4.14; today's close sits at 3% of that range, 47.6% below the 52-week high.
Oct 12, 2026 — BLRX dips 2.3% to $2.17, a 52-week low
- Closed at $2.17, -2.25% vs the prior close of $2.22. Day range $2.14–$2.34, opened at $2.22.
- Volume was 28.20K shares, 1.5x its 50-day average of 18.24K.
- Price is -16.2% vs its 50-day average ($2.59) and -22.5% vs its 200-day average ($2.80).
- 52-week range $2.14–$4.16; today's close sits at 1% of that range, 47.8% below the 52-week high.
Oct 9, 2026 — BLRX rises 0.5% to $2.22
- Closed at $2.22, +0.45% vs the prior close of $2.21. Day range $2.20–$2.27, opened at $2.20.
- Volume was 9.70K shares, 0.5x its 50-day average of 18.18K — lighter than usual.
- Price is -14.6% vs its 50-day average ($2.60) and -20.8% vs its 200-day average ($2.80).
- 52-week range $2.15–$4.50; today's close sits at 3% of that range, 50.7% below the 52-week high.
Oct 8, 2026 — BLRX ends flat (+0.0%) to $2.21, 4 down days in a row
- Closed at $2.21, +0.00% vs the prior close of $2.21. Day range $2.17–$2.31, opened at $2.31.
- Volume was 18.40K shares, 1.0x its 50-day average of 17.93K.
- Price is -15.3% vs its 50-day average ($2.61) and -21.2% vs its 200-day average ($2.81).
- 52-week range $2.15–$4.54; today's close sits at 3% of that range, 51.3% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — BLRX slides 3.5% to $2.21, a 6-month low, 3 down days in a row
- Closed at $2.21, -3.49% vs the prior close of $2.29. Day range $2.16–$2.37, opened at $2.28.
- Volume was 24.00K shares, 1.4x its 50-day average of 17.77K.
- Price is -15.7% vs its 50-day average ($2.62) and -21.4% vs its 200-day average ($2.81).
- 52-week range $2.15–$4.56; today's close sits at 2% of that range, 51.5% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — BLRX dips 1.3% to $2.29, a 3-month low
- Closed at $2.29, -1.29% vs the prior close of $2.32. Day range $2.26–$2.40, opened at $2.31.
- Volume was 22.90K shares, 1.3x its 50-day average of 17.41K.
- Price is -13.0% vs its 50-day average ($2.63) and -18.6% vs its 200-day average ($2.81).
- 52-week range $2.15–$4.56; today's close sits at 6% of that range, 49.8% below the 52-week high.
Oct 5, 2026 — BLRX dips 2.1% to $2.32, a 3-month low
- Closed at $2.32, -2.11% vs the prior close of $2.37. Day range $2.29–$2.36, opened at $2.36.
- Volume was 20.30K shares, 1.2x its 50-day average of 17.06K.
- Price is -12.3% vs its 50-day average ($2.64) and -17.6% vs its 200-day average ($2.82).
- 52-week range $2.15–$4.56; today's close sits at 7% of that range, 49.1% below the 52-week high.
Oct 2, 2026 — BLRX rises 0.9% to $2.37
- Closed at $2.37, +0.85% vs the prior close of $2.35. Day range $2.31–$2.37, opened at $2.31.
- Volume was 3.10K shares, 0.2x its 50-day average of 17.16K — lighter than usual.
- Price is -10.7% vs its 50-day average ($2.65) and -16.0% vs its 200-day average ($2.82).
- 52-week range $2.15–$4.56; today's close sits at 9% of that range, 48.0% below the 52-week high.
BLRX latest news & SEC filings
Every SEC filing by or about BLRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 25, 2026 · Form F-1 — F-1 filing
F-1 filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 24, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 10, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 31, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 28, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade BLRX
- How much it moves: over the last 20 sessions the average daily move was 2.02% (largest 6.5%).
- Liquidity: about 16.88K shares (≈$33.93K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.01 vs a range of $1.95–$4.07 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:40 on Jan 30, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Sep 24, 2026; 6-K Sep 10, 2026; 6-K Aug 31, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BLRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.30 | 2.30 | 1.99 | 2.01 | 12.58K |
| Oct 15, 2026 | 2.03 | 2.17 | 1.95 | 2.05 | 28.80K |
| Oct 14, 2026 | 2.18 | 2.18 | 2.01 | 2.08 | 23.50K |
| Oct 13, 2026 | 2.27 | 2.27 | 2.11 | 2.17 | 11.70K |
| Oct 12, 2026 | 2.22 | 2.34 | 2.14 | 2.17 | 28.20K |
| Oct 9, 2026 | 2.20 | 2.27 | 2.20 | 2.22 | 9.70K |
| Oct 8, 2026 | 2.31 | 2.31 | 2.17 | 2.21 | 18.40K |
| Oct 7, 2026 | 2.28 | 2.37 | 2.16 | 2.21 | 24.00K |
| Oct 6, 2026 | 2.31 | 2.40 | 2.26 | 2.29 | 22.90K |
| Oct 5, 2026 | 2.36 | 2.36 | 2.29 | 2.32 | 20.30K |
| Oct 2, 2026 | 2.31 | 2.37 | 2.31 | 2.37 | 3.10K |
| Oct 1, 2026 | 2.32 | 2.39 | 2.32 | 2.35 | 7.60K |
| Sep 30, 2026 | 2.36 | 2.40 | 2.30 | 2.35 | 40.80K |
| Sep 29, 2026 | 2.41 | 2.50 | 2.36 | 2.36 | 12.10K |
| Sep 28, 2026 | 2.50 | 2.50 | 2.41 | 2.43 | 12.50K |
| Sep 25, 2026 | 2.49 | 2.60 | 2.49 | 2.60 | 9.90K |
| Sep 24, 2026 | 2.56 | 2.59 | 2.44 | 2.52 | 11.30K |
| Sep 23, 2026 | 2.53 | 2.57 | 2.45 | 2.56 | 12.70K |
| Sep 22, 2026 | 2.48 | 2.60 | 2.42 | 2.43 | 10.40K |
| Sep 21, 2026 | 2.53 | 2.58 | 2.45 | 2.48 | 17.10K |
About BioLineRx
BioLineRx (BLRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MODI-IN. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1498403.
BLRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Barbara-Jean Anne Bormann-Kennedy | Director | Mar 18, 2026 |
| Gal Avraham Cohen | Director | Mar 30, 2026 |
| Rami Dar | Director | Mar 31, 2026 |
| Raphael Hofstein | Director | Mar 31, 2026 |
| Avraham Molcho | Director | Mar 31, 2026 |
| Sandra Panem | Director | Mar 31, 2026 |
| Aharon Schwartz | Director | Mar 30, 2026 |
| Shaoyu Yan | Director | Apr 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Philip A Serlin | Chief Executive Officer | Mar 27, 2026 |
| Mali Zeevi | Chief Financial Officer | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
BLRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
BLRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BLRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.